Company: HQL
Filing Date: 2025-06-09
Form Type: N-CSRS
Source: 0001104659-25-057746
Chunk: 20

Company: abrdn Life Sciences Investors
Filing Date: 2025-06-09
Form: N-CSRS
Chunk 20
---
 (the "Fund's Portion"). However, investor relations services fees are limited by Aberdeen so that the Fund will only pay up to an annual rate of 0.05% of the Fund's average weekly net assets. Any difference between the capped rate of 0.05% of the Fund's average weekly net assets and the Fund's Portion is paid for by Aberdeen. Pursuant to the terms of the Investor Relations Services Agreement, abrdn Inc. (or third parties engaged by Aberdeen), among other things, provides objective and timely information to shareholders based on publicly-available information; provides information efficiently through the use of technology while offering shareholders immediate access to knowledgeable investor relations representatives; develops and maintains effective communications with investment professionals from a wide variety of firms; creates and maintains investor relations communication materials such as fund manager interviews, films and webcasts, publishes white papers, magazine articles and other relevant materials discussing the Fund's investment results, portfolio positioning and outlook; develops and maintains effective communications with large institutional shareholders; responds to specific shareholder questions; and reports activities and results to the Board and management detailing insight into general shareholder sentiment. During the six-month period ended March 31, 2025, the Fund incurred investor relations fees of approximately $28,263. For the six-month period ended March 31, 2025, Aberdeen did not contribute to the

| 22 | abrdn Life Sciences Investors |

Notes to Financial Statements (unaudited) (continued) March 31, 2025 investor relations fees for the Fund because the Fund’s contribution was below 0.05% of the Fund’s average weekly net assets on an annual basis.

4. Investment Transactions Purchases and sales of investment securities (excluding short-term securities) for the six-month period ended March 31, 2025, were $163,994,164 and $167,200,605, respectively. 5. Capital The Fund is authorized to issue an unlimited number of common shares of beneficial interest at par value $0.01 per common share. As of March 31, 2025, there were 28,872,416 shares of common stock issued and outstanding. The following table shows the shares issued by the Fund as a part of a quarterly distribution to shareholders during the fiscal year ended March 31, 2025.

| Payment Date     | Shares Issued |
| January 10, 2025 |       404,917 |
| March 31, 2025   |       406,100 |

6